Your browser doesn't support javascript.
loading
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Grivas, P; Loriot, Y; Morales-Barrera, R; Teo, M Y; Zakharia, Y; Feyerabend, S; Vogelzang, N J; Grande, E; Adra, N; Alva, A; Necchi, A; Rodriguez-Vida, A; Gupta, S; Josephs, D H; Srinivas, S; Wride, K; Thomas, D; Simmons, A; Loehr, A; Dusek, R L; Nepert, D; Chowdhury, S.
Afiliação
  • Grivas P; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, 98109, USA. pgivas@uw.edu.
  • Loriot Y; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA. pgivas@uw.edu.
  • Morales-Barrera R; Seattle Cancer Care Alliance, 1144 Eastlake Avenue E, LG- 465, Seattle, WA, 98109, USA. pgivas@uw.edu.
  • Teo MY; Department of Medicine, Gustave Roussy Cancer Campus, INSERM U981, Université Paris-Saclay, 39 Rue Camille Desmoulins, 94800, Villejuif, France.
  • Zakharia Y; Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.
  • Feyerabend S; Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Vogelzang NJ; Division of Hematology, Oncology, and Blood and Marrow Transplant, University of Iowa and Holden Comprehensive Cancer Center, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
  • Grande E; Studienpraxis Urologie, Steinengrabenstraße 17, 72622, Nürtingen, Germany.
  • Adra N; Division of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, 3730 S Eastern Avenue, Las Vegas, NV, 89169, USA.
  • Alva A; Department of Medical Oncology, MD Anderson Cancer Center, Calle de Arturo Soria, 270 28033, Madrid, Spain.
  • Necchi A; Department of Medicine, Indiana University Simon Cancer Center, 535 Barnhill Drive, Indianapolis, IN, 46202, USA.
  • Rodriguez-Vida A; Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI, 48109, USA.
  • Gupta S; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133, Milan, Italy.
  • Josephs DH; Medical Oncology Department, Hospital del Mar, Passeig Maritim 25-29, 08003, Barcelona, Spain.
  • Srinivas S; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, 1950 Circle of Hope, Salt Lake City, UT, 84112, USA.
  • Wride K; Department of Medical Oncology, Guy's and St. Thomas' NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UK.
  • Thomas D; Division of Medical Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA.
  • Simmons A; Clovis Oncology, Inc., 5500 Flatiron Parkway, Boulder, CO, 80301, USA.
  • Loehr A; Clovis Oncology, Inc., 5500 Flatiron Parkway, Boulder, CO, 80301, USA.
  • Dusek RL; Clovis Oncology, Inc., 5500 Flatiron Parkway, Boulder, CO, 80301, USA.
  • Nepert D; Clovis Oncology, Inc., 5500 Flatiron Parkway, Boulder, CO, 80301, USA.
  • Chowdhury S; Clovis Oncology, Inc., 5500 Flatiron Parkway, Boulder, CO, 80301, USA.
BMC Cancer ; 21(1): 593, 2021 May 24.
Article em En | MEDLINE | ID: mdl-34030643
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Inibidores de Poli(ADP-Ribose) Polimerases / Indóis Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Inibidores de Poli(ADP-Ribose) Polimerases / Indóis Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article